Pfizer Inc.

Pfizer expects revenue and profit to decline in 2026 due to weaker demand for vaccines and other products related to Covid-19. Analysts note that the company is trying to offset the pressure on its performance by cutting costs and increasing investments in research and development, but do not see any significant drivers for the stock's revaluation in the coming year.

Pfizer expects performance to fall due to lower sales of Covid vaccines. Shares fall

The fair value of Soligenix, a micro-cap pharmaceutical company, is estimated to be 800% higher than the current share price, according to a recent report by Zacks Small-Cap Research (Zacks SCR). Soligenix is developing several products, chief among which is a vaccine for the deadly, hemorrhagic-fever-causing Marburg virus. It is in the spotlight following a recent outbreak in Rwanda.

Vaccine